High prevalence of anti-HGV/E2 antibodies in HCV-positive patients with non Hodgkin's lymphoma.
We evaluated in a series of 33 HCV positive (both RT-PCR and HCV RIBA 2 assays) B cell non-Hodgkin's lymphomas (NHL) patients the prevalence of active and inactive HGV infection by HGV RNA assays (RT-PCR) and anti HGV antibodies directed against E2 structural protein (immunoenzimatic method), a reliable serologic marker of past HGV infection followed by viral clearance. We found only one patient with HGV positivity at RT-PCR (3%). Twenty-six of 33 patients were positive for anti HGV/E2 antibodies (78.8%) suggesting past infection. If confirmed, our preliminary data seem to suggest a higher incidence of HGV past infection in our group of HCV positive patients with B cell NHL.
Civardi
G
G
Tanzi
E
E
Ferrari
B
B
Vallisa
D
D
Zanetti
A
A
Cavanna
L
L
D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D018067:Flaviviridae / Q000276:immunology*; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000150:complications* / Q000276:immunology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; C107619:glycoprotein E2, GB virus C